Curium: Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis

The acquisition of Nucleis will: Enhance Curium's PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET diagnostics for patients in Benelux and Germany Expand CDMO capabilities to support the development of innovative PET tracers in oncology, neurology, and cardiology PARIS, April 10, 2025 [...]The post Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis appeared first on Be Korea-savvy.